ADO and neoplasm: All in, PRMT5 interacts with CD38 activating the phosphorylation of GSK3β through the ADO-cAMP-PKA axis, augmenting stabilization of PD-L1 expression and subsequently inhibiting CD8+ T cell-mediated tumor cell killing, supporting tumor cells to evade immune surveillance (Figure 4) [75].